RE:G12D/G12V KRAS mutation in PC & CRC patients respond to PelaOctober 02, 2024 - The clinical ranks for the development of a KRAS G12D inhibitor will now be swelled by Lilly’s LY3962673, which had preclinical data at this year’s AACR, and which has just entered phase 1. Pfizer’s pan-KRAS challenger, PF-07934040, entered its first-in-human study in July, and now two other newcomers, BeiGene and Lilly, have joined the fray. The projects in question, BGB-53038 and LY4066434 respectively, were both unveiled in pipeline updates last year, and by the end of 2024 both will be in human studies.
A notable difference is that the Pfizer and BeiGene trials both exclude patients who have been previously treated with any RAS or KRAS inhibitor. Lilly’s, however, does not, at least according to clinicaltrials.gov.